ECI is a biopharma company dedicated to the development, commercialization, and marketing of specialty human plasma/serum-derived drugs for ophthalmic conditions; wound healing; and burns. Leveraging a novel molecule to enhance consistency, and decrease the risk of pathogenicity, ECI seeks to harness the power of blood to heal.
External link for ECI Therapeutics
700 Main St
Cambridge, Massachusetts 02139, US
ECI Therapeutics reposted this
We are hiring a Scientist /Scientist II with experience in blood and Biologics in the Cambridge area! Do you know anyone who might be interested? LabCentral, Boston Cambridge Biotech Networks MassBio #hiring #Science #blood #biologics #biotech
We can’t say enough good things about LabCentral! Its much more than amazing laboratory facilities, it’s the LabCentral team, co-residents who are eager to help one another, and extensive training and networking opportunities!
ECI Therapeutics moved into LabCentral back in October to continue their work developing breakthrough products for #eyecare, #woundcare, and #burnhealing that leverage its #plasma and #chitosan platform technology. We were lucky enough to catch CEO of ECI Therapeutics, Elan Weiner, during a rare break in his busy schedule to check in on his experience at LabCentral so far. Here's what he had to say: "LabCentral is not just a facility; it's a dynamic, nurturing ecosystem that propels forward-thinking companies, and being a resident signals credibility to many in the biotech space. For ECI Therapeutics, LabCentral is more than a location; it's our strategic partner and our supporter. It’s a springboard for our vision and our momentum." While still relatively new to our space, we're so proud to have made a significant impact on their startup journey. We look forward to seeing what your team will accomplish! 🤩
Fantastic to read the Governor Healey is reauthorizing the #lifescience Initiative to build on the success of the program that has made #Massachusetts a global leader in this critical industry. She also announced that she is applying this proven model to a new #climatetech Initiative, which will position Massachusetts to compete on the global stage in this emerging industry. #biotech ECI Therapeutics
In mid-February I was fortunate enough to celebrate Governor Maura Healey’s birthday with her and her amazing team. At this event and the two others where I saw her in recent weeks the Governor stressed the importance of the biotech sector to Massachusetts and the importance of Massachusetts to the biotech sector. This past Friday Governor Healey took action to advance her goal of mutual success. Together we can improve the lives of those living in the Commonwealth and around the globe! https://lnkd.in/gJNJV8Ai Office of Massachusetts Governor Maura Healey #lifesciences #biotech #massachusetts #pharmaceutical #cambridgema #boston #investment #inclusion
ECI will be represented at #jpm2024 and #biotechshowcase 2024 by our CEO Elan Weiner. We’re looking forward to connecting in San Francisco! #biotech #jpmorgan #eyehealth
I'm excited to attend Biotech Showcase 2024, January 8–10, 2024 in San Francisco. Join me to meet one-to-one! https://lnkd.in/eFpxPrGB #jpm2024 #jpm24 #healthcare #biotech #seriesa #eyehealth #sanfrancisco #venturecapital ECI Therapeutics
Pathogen Safety: A Critical Step in Ophthalmic — and All — Drug Manufacturing.
~Pathogen Safety in Ophthalmic Products~ In light of the recent recall involving 26 ophthalmic products due to bacterial contamination risks, it's a stark reminder of the imperative for stringent pathogen safety protocols in all areas of drug manufacturing. Reflecting on historical lessons from incidents such as the widespread Fusarium keratitis outbreak linked to contact lens solution in 2006, which highlighted the catastrophic impact of microbial contamination, underscores the importance of this issue, for bactial and fungal risk alike. As we venture further into the realm of biologics, with treatments like allogeneic plasma eye drops for Dry Eye Disease (DED), the rigor and extent of safety measures must be heightened, and expanded to protect against viruses. Ensuring the sterility and safety of these complex products is not just regulatory compliance, but a fundamental responsibility to protect patients' sight and trust in ophthalmic care. ECI maintains equal focus on developing drugs for ophthalmic conditions and modalities to reduce pathogen risk in eye products of biological origin.